Brought to you by 
Serono, ZymoGenetics to develop proteins
15 Sep 2004
Executive Summary
In a deal that grew out of their 2001 collaboration on autoimmune therapeutics, Serono SA has licensed exclusive worldwide rights to three of ZymoGenetics's preclinical proteins: fibroblast growth factor 18 (FGF-18, for treating cartilage damaged by osteoarthritis or physical injury), interleukin 22 receptor (IL-22R, psoriasis), and interleukin 31 (IL-31, an anti-inflammatory for asthma, IBD, psoriasis, and potentially atopic dermatitis; ZG retains co-development and co-commercialization rights in the US for this one). For these projects, Serono will pay $11.25mm in up-front licensing fees, plus milestones that could exceed $100mm.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Large Molecule
Deal Status
- Final
Deal Type
-
Alliance
- Co-Promotion
- Includes Contract
- Includes Equity
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Serono, ZymoGenetics to develop proteins
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice